SMAD4 and neoplasm: In addition, our findings demonstrated that patients within Immune Class had a significantly lower frequency of mutations in SMAD4. The loss of SMAD4 was previously reported to regulate the cell cycle and promote tumor proliferation and indicated poor survival in PDAC patients (61, 62).